2nd Annual Orphan Drug Congress 2012
Congress - Barcelona, Spain
Treatments of rare diseases has long represented market niche in the pharmaceutical industry. Recently the importance of developing medicines for rare and obscure diseases have forced traditional pharma companies to re-evaluate their position on orphan and ultra orphan drugs. Despite the incentives relating to marketing exclusivity, taxes and fees, protocol design and research grants for the development of orphan drugs, there remain significant challenges.
This year's conference will discuss the major concerns, newest challenges and the best practices in the development of orphan drugs. The use of patient registries, open innovation in rare diseases, designation, the importance of communication between pharma, patients and HTA bodies, use of social media and many more will be covered by the au fait pharmaceutical representatives.
Thursday, June 7, 2012 - Friday, June 8, 2012
Barcelona, Spain
If you'd like to ask a question or post a comment about this talk please do so below.
This seminar posting is brought to you by Biotechnology Calendar, Inc. providing access to research information and research tools for nearly 20 years. Visit our Science Market Update Blog for current science funding and market information or see our schedule of upcoming science research laboratory product shows.
